Overview

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving everolimus together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin in treating older patients with newly diagnosed acute myeloid leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Treatments:
Carboplatin
Cytarabine
Etoposide
Etoposide phosphate
Everolimus
Idarubicin
Ifosfamide
Mitoxantrone
Sirolimus